OTC Allergy Switch Approved For Bayer In US

Azelastine 0.15% Nasal Antihistamine Branded Astepro Allergy Is First-In-Class Switch

CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.

Bayer AG adds a brand to its US OTC allergy remedy lineup as the Food and Drug Administration adds a first-in-class ingredient to the products it has approved for nonprescription sales with a partial OTC switch of azelastine hydrochloride nasal spray, 0.15%.

The FDA’s Center for Drug Evaluation and Research on 17 June announced approval of an application Bayer Healthcare LLC submitted...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health